Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable
Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies
in the treatment of coronary heart disease.